Table 1.
Description of the 44 cases of cervical cancer following an index Pap−/HPV+ cotesting result in women 30 and older
| All | 2003-5 | 2005-9 | |||||
|---|---|---|---|---|---|---|---|
| N | col% | N | col% | N | col% | p | |
| Age at 1st Pap−/HPV+ result | |||||||
| <40 | 20 | 45% | 13 | 42% | 7 | 54% | 0.9 |
| 40-49 | 15 | 34% | 11 | 35% | 4 | 31% | |
| 50-59 | 6 | 14% | 5 | 16% | 1 | 8% | |
| 60+ | 3 | 7% | 2 | 6% | 1 | 8% | |
| Age at Cancer Diagnosis | |||||||
| <40 | 19 | 43% | 12 | 39% | 7 | 54% | 0.8 |
| 40-49 | 16 | 36% | 12 | 39% | 4 | 31% | |
| 50-59 | 6 | 14% | 5 | 16% | 1 | 8% | |
| 60+ | 3 | 7% | 2 | 6% | 1 | 8% | |
| Number of Pap−/HPV+ before Diagnosis | |||||||
| 1 | 25 | 57% | 16 | 52% | 9 | 69% | 0.7 |
| 2 | 15 | 34% | 12 | 39% | 3 | 23% | |
| 3 | 4 | 9% | 3 | 10% | 1 | 8% | |
| Number of Screens after 1st Pap−/HPV+ | |||||||
| 0 | 12 | 27% | 7 | 23% | 5 | 38% | 0.1 |
| 1 | 17 | 39% | 10 | 32% | 7 | 54% | |
| 2 | 12 | 27% | 11 | 35% | 1 | 8% | |
| 3 | 3 | 7% | 3 | 10% | 0 | 0% | |
| Time between 1st Pap−/HPV+ and Last Co-test † | |||||||
| ≤12 months | 7 | 22% | 2 | 9% | 5 | 56% | 0.01 |
| 12-18 months | 8 | 25% | 5 | 22% | 3 | 33% | |
| 18-24 months | 5 | 16% | 5 | 22% | 0 | 0% | |
| ≥24 months | 12 | 38% | 11 | 48% | 1 | 11% | |
| Final Co-testing Results before Diagnosis | |||||||
| Pap+/HPV+* | 27 | 61% | 21 | 68% | 6 | 46% | 0.3 |
| Pap−/HPV+ (includes unsatisfactory Paps) | 17 | 39% | 10 | 32% | 7 | 54% | |
| Pap+/HPV− | 0 | 0% | 0 | 0% | 0 | 0% | |
| Pap−/HPV− | 0 | 0% | 0 | 0% | 0 | 0% | |
| Cancer Histology | |||||||
| adenocarcinoma | 24 | 55% | 16 | 52% | 8 | 62% | 0.6 |
| adenocarcinoma & squamous | 1 | 2% | 0 | 0% | 1 | 8% | |
| adenosquamous | 2 | 5% | 2 | 6% | 0 | 0% | |
| small cell | 1 | 2% | 1 | 3% | 0 | 0% | |
| squamous | 16 | 36% | 12 | 39% | 4 | 31% | |
| Figo Stage | |||||||
| IA | 11 | 25% | 10 | 32% | 1 | 8% | 0.2 |
| IB | 31 | 70% | 20 | 65% | 11 | 85% | |
| IIA | 2 | 5% | 1 | 3% | 1 | 8% | |
| Pelvic Node Dissection | |||||||
| No | 14 | 32% | 7 | 23% | 7 | 54% | 0.2 |
| Yes and Negative | 28 | 64% | 20 | 65% | 8 | 62% | |
| Yes and Positive | 2 | 5% | 2 | 6% | 0 | 0% | |
| Treatment | |||||||
| Chemoradiation | 8 | 18% | 3 | 10% | 5 | 38% | 0.07 |
| Surgery | 33 | 75% | 26 | 84% | 7 | 54% | |
| Surgery& Chemoradiation | 3 | 7% | 2 | 6% | 1 | 8% | |
†
Restricted to those who had at least one additional cotest
*
Includes cytologic interpretations of squamous cell cancer (n = 2), high-grade squamous intraepithelial lesion (HSIL) or adenocarcinoma in situ (n = 8), atypical glandular cells (AGC) (n = 6), atypical squamous cells (ASC) or ASC, cannot rule out HSIL (ASC-H) (n = 8), ASC-H/AGC (n = 1), and LSIL (n = 2).